Cargando…

Second-line therapy for patients with steroid-refractory aGVHD: systematic review and meta-analysis of randomized controlled trials

OBJECTIVE: Steroids-refractory (SR) acute graft-versus-host disease (aGVHD) is a life-threatening condition in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the optimal second-line therapy still has not been established. We aimed to perform a systematic revi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Chengxin, Huang, Xiangtao, Wei, Ling, Wu, Guixian, Huang, Yarui, Ding, Yaqun, Huang, Zhen, Chen, Jieping, Li, Xi, Zou, Yunding, Xu, Shuangnian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318925/ https://www.ncbi.nlm.nih.gov/pubmed/37409129 http://dx.doi.org/10.3389/fimmu.2023.1211171

Ejemplares similares

Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy
por: Yang, Jingjing, et al.
Publicado: (2021)

Current Preventions and Treatments of aGVHD: From Pharmacological Prophylaxis to Innovative Therapies
por: Naserian, Sina, et al.
Publicado: (2020)

Efficacy of hematopoietic stem cell mobilization regimens in patients with hematological malignancies: a systematic review and network meta-analysis of randomized controlled trials
por: Luo, Chengxin, et al.
Publicado: (2022)

Steroid-resistant intestinal aGVHD and refractory CMV and EBV infections complicated by haplo-HSCT were successfully rescued by FMT and CTL infusion
por: Qi, Ling, et al.
Publicado: (2021)

Prognostic Role of Serum Albumin Level in Patients with Lymphoma Undergoing Autologous Stem Cell Transplantation
por: Luo, Chengxin, et al.
Publicado: (2021)

Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation
por: Song, Yuan, et al.
Publicado: (2020)

Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20(+) B-cell non-Hodgkin lymphomas: a systematic review and meta-analysis
por: Luo, Chengxin, et al.
Publicado: (2021)

Tyrosine supplement ameliorates murine aGVHD by modulation of gut microbiome and metabolome
por: Li, Xiaoqing, et al.
Publicado: (2020)

Intestinal aGVHD and infection after hematopoietic stem cell transplantation
por: Hou, Cai-yan, et al.
Publicado: (2013)

Comparison of the efficacy of hematopoietic stem cell mobilization regimens: a systematic review and network meta-analysis of preclinical studies
por: Luo, Chengxin, et al.
Publicado: (2021)

Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation
por: Zhu, Jinye, et al.
Publicado: (2023)

High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials
por: Gong, Qiang, et al.
Publicado: (2015)

Genetic polymorphisms of NAT2 and risk of acute myeloid leukemia: A case-control study
por: Zou, Yunding, et al.
Publicado: (2017)

Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD)
por: Efebera, Yvonne A, et al.
Publicado: (2019)

Human Amniotic Mesenchymal Stem Cells Inhibit aGVHD by Regulating Balance of Treg and T Effector Cells
por: Gao, Ya, et al.
Publicado: (2021)

Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation
por: Shokouhi, Shabnam, et al.
Publicado: (2015)

Steroid-Refractory Acute GVHD: Predictors and Outcomes
por: Westin, Jason R., et al.
Publicado: (2011)

The Potential Genes Mediate the Pathogenicity of Allogeneic CD4(+)T Cell in aGVHD Mouse Model
por: Yu, Zhengyu, et al.
Publicado: (2021)

Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes
por: Herzog, Shannon, et al.
Publicado: (2023)

Modulating endothelial cells with EGFL7 to diminish aGVHD after allogeneic bone marrow transplantation in mice
por: Dorrance, Adrienne M., et al.
Publicado: (2022)

Berberine ameliorates aGVHD by gut microbiota remodelling, TLR4 signalling suppression and colonic barrier repairment for NLRP3 inflammasome inhibition
por: Zhao, Yanna, et al.
Publicado: (2022)

Safety and Efficacy of Fecal Microbiota Transplantation for Grade IV Steroid Refractory GI-GvHD Patients: Interim Results From FMT2017002 Trial
por: Zhao, Ye, et al.
Publicado: (2021)

Prognostic Significance of CD56 Antigen Expression in Patients with De Novo Non-M3 Acute Myeloid Leukemia
por: Sun, Yanni, et al.
Publicado: (2021)

Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage
por: He, Xin, et al.
Publicado: (2016)

Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGVHD
por: He, Fiona, et al.
Publicado: (2016)

The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation
por: Zuo, Wei, et al.
Publicado: (2022)

Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
por: Sobash, Philip T., et al.
Publicado: (2020)

Fluvastatin-Pretreated Donor Cells Attenuated Murine aGVHD by Balancing Effector T Cell Distribution and Function under the Regulation of KLF2
por: Zhao, Kai, et al.
Publicado: (2020)

Compound A Increases Cell Infiltration in Target Organs of Acute Graft-versus-Host Disease (aGVHD) in a Mouse Model
por: Bouazzaoui, Abdellatif, et al.
Publicado: (2021)

SENP1 promotes MCL pathogenesis through regulating JAK-STAT5 pathway and SOCS2 expression
por: Zhang, Yali, et al.
Publicado: (2021)

GVHD Prophylaxis 2020
por: Gooptu, Mahasweta, et al.
Publicado: (2021)

Adipose tissue-derived stem cells modulate immune function in vivo and promote long-term hematopoiesis in vitro using the aGVHD model
por: Jiang, Ming, et al.
Publicado: (2020)

Tumor necrosis factor α in aGVHD patients contributed to the impairment of recipient bone marrow MSC stemness and deficiency of their hematopoiesis-promotion capacity
por: Ding, Li, et al.
Publicado: (2020)

Therapeutic Effects of HLA-G5 Overexpressing hAMSCs on aGVHD After Allo-HSCT: Involving in the Gut Microbiota at the Intestinal Barrier
por: Bu, Xiaoyin, et al.
Publicado: (2023)

Human Amniotic Mesenchymal Stem Cells Alleviate aGVHD after allo-HSCT by Regulating Interactions between Gut Microbiota and Intestinal Immunity
por: Bu, Xiaoyin, et al.
Publicado: (2023)

Metabolic Reprogramming of Alloreactive T Cells Through TCR/MYC/mTORC1/E2F6 Signaling in aGvHD Patients
por: Pan, Zengkai, et al.
Publicado: (2022)

Editorial: Interferons and GvHD
por: Kim, Boram, et al.
Publicado: (2022)

Regulatory T Cells in GVHD Therapy
por: Guo, Wen-wen, et al.
Publicado: (2021)

Milestones in acute GVHD pathophysiology
por: Socie, Gerard, et al.
Publicado: (2022)

Three-dimensional structure discrepancy between HLA alleles for effective prediction of aGVHD severity and optimal selection of recipient-donor pairs: a proof-of-concept study
por: Han, Hongxing, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_342fv8b2nob0b2gu1lp538iphd